The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of Texas System

Memgen, Inc.

Yeda Research and Develpment & Co. Ltd

Nanocruise Pharmaceutical Ltd.

Patrick Hwu

Steven A Rosenberg

Maria R Parkhurst

Rejean LaPointe

Mark J Cantwell

Willem Overwijk

Manisha Singh

Mark Reeves

Zelig Eshhar

Tova Waks

Laszlo Radvanyi

Cassian Yee

Gideon Gross

Janos Roszik

Gregory Lizée

Daniel Schindler

Jodi A McKenzie

Dapeng Zhou

Rina M Mbofung

Chantale Bernatchez

Rodabe Amaria

Michael H Kershaw

Rina N Mbofung

Shruti Malu

Willem W Overwijk

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of a TLR agonist and a chimeric CD154 polypeptide. Also provided herein are methods of enhanced immune function.

Methods of CD40 and toll like receptor immune activation

The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.

Monoclonal and humanized antibodies to a cancer glycopeptide

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.

Methods of CD40 activation and immune checkpoint blockade

The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an &#x3b1;-PD-L1 antibody.

Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

BTLA-positive ('BTLA+') lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.

B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.

Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods

Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.

Chimeric receptor genes and cells transformed therewith

The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.

Activated dual specificity lymphocytes and their methods of use

Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods

Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.

Methods and compositions for transforming dendritic cells and activating T cells

Growing community of inventors

Houston, TX, United States of America

Patrick Hwu